Pharmacy Daily | Vimpat and Mircera

A NEW anti-epileptic medication, VIMPAT (lacosamide), has been approved for use on the Pharmaceutical Benefits Sheme from 01 May. VIMPAT has been approved for use in people aged over 16 years who suffer uncontrolled partial onset epilepsy (focal epilepsy) and have already tried and failed a number of first and second-line anti-epileptic drugs. MEANWHILE the first continuous erythropoietin receptor activator that offers once monthly maintenance dosing for patients with anaemia associated with chronic kidney disease, MIRCERA (methoxy polyethylene glycolepoetin beta, is now available to patients on the PBS. Other benefits of MIRCERA include no refrigeration required, with the once per month injections also offering a reduction of up to 80% in nursing time spent managing renal anaemia to improve health system efficiency.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 10
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 10